美银证券发表研究报告指出,中国生物制药(01177.HK) 宣布,已与赛诺菲就其中国生物制药的JAK/ROCK抑制剂罗伐昔替尼的全球(包括中国)开发、制造及商业化订立独家许可协议。中国生物制药可获得1.35亿美元的首付款,加上最高达13.95亿美元的潜在开发、监管及销售里程碑付款,以及基于罗伐昔替尼年度净销售额的分级特许权使用费。该行认为,与跨国药企赛诺菲达成授权许可交易,是中国生物制药内部研发...
Source Link美银证券发表研究报告指出,中国生物制药(01177.HK) 宣布,已与赛诺菲就其中国生物制药的JAK/ROCK抑制剂罗伐昔替尼的全球(包括中国)开发、制造及商业化订立独家许可协议。中国生物制药可获得1.35亿美元的首付款,加上最高达13.95亿美元的潜在开发、监管及销售里程碑付款,以及基于罗伐昔替尼年度净销售额的分级特许权使用费。该行认为,与跨国药企赛诺菲达成授权许可交易,是中国生物制药内部研发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.